Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C34H29ClN6O3 |
Molecular Weight | 605.085 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)C1=C(NC(C)=C([C@H]1C2=CC=CC=C2Cl)C(=O)NC3=NC=CC=C3)C4=CC=C(C=C4)N5C(C)=NC6=C5C=CN=C6
InChI
InChIKey=ODRYSCQFUGFOSU-SSEXGKCCSA-N
InChI=1S/C34H29ClN6O3/c1-4-44-34(43)31-30(24-9-5-6-10-25(24)35)29(33(42)40-28-11-7-8-17-37-28)20(2)38-32(31)22-12-14-23(15-13-22)41-21(3)39-26-19-36-18-16-27(26)41/h5-19,30,38H,4H2,1-3H3,(H,37,40,42)/t30-/m1/s1
Molecular Formula | C34H29ClN6O3 |
Molecular Weight | 605.085 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Modipafant is a dihydropyridine derivative patented by American multinational pharmaceutical corporation Pfizer Ltd. as platelet-activating factor antagonist for bronchoconstriction and asthma treatment. Platelet-activating factor, proposed as an important inflammatory mediator in asthma, reproduces several of the features of asthma, such as microvascular leakage, mucus secretion, bronchoconstriction, and possibly increased airway responsiveness. Unfortunately, in clinical trials, Modipafant failed to demonstrate superior efficacy compared to placebo.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7735582
50 mg capsule twice daily
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:02:54 GMT 2023
by
admin
on
Fri Dec 15 16:02:54 GMT 2023
|
Record UNII |
1DMI0E5023
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1327
Created by
admin on Fri Dec 15 16:02:54 GMT 2023 , Edited by admin on Fri Dec 15 16:02:54 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C073027
Created by
admin on Fri Dec 15 16:02:54 GMT 2023 , Edited by admin on Fri Dec 15 16:02:54 GMT 2023
|
PRIMARY | |||
|
1DMI0E5023
Created by
admin on Fri Dec 15 16:02:54 GMT 2023 , Edited by admin on Fri Dec 15 16:02:54 GMT 2023
|
PRIMARY | |||
|
DTXSID30153811
Created by
admin on Fri Dec 15 16:02:54 GMT 2023 , Edited by admin on Fri Dec 15 16:02:54 GMT 2023
|
PRIMARY | |||
|
SUB09029MIG
Created by
admin on Fri Dec 15 16:02:54 GMT 2023 , Edited by admin on Fri Dec 15 16:02:54 GMT 2023
|
PRIMARY | |||
|
6828
Created by
admin on Fri Dec 15 16:02:54 GMT 2023 , Edited by admin on Fri Dec 15 16:02:54 GMT 2023
|
PRIMARY | |||
|
100000080350
Created by
admin on Fri Dec 15 16:02:54 GMT 2023 , Edited by admin on Fri Dec 15 16:02:54 GMT 2023
|
PRIMARY | |||
|
CHEMBL2105829
Created by
admin on Fri Dec 15 16:02:54 GMT 2023 , Edited by admin on Fri Dec 15 16:02:54 GMT 2023
|
PRIMARY | |||
|
122957-06-6
Created by
admin on Fri Dec 15 16:02:54 GMT 2023 , Edited by admin on Fri Dec 15 16:02:54 GMT 2023
|
PRIMARY | |||
|
C90752
Created by
admin on Fri Dec 15 16:02:54 GMT 2023 , Edited by admin on Fri Dec 15 16:02:54 GMT 2023
|
PRIMARY | |||
|
3047770
Created by
admin on Fri Dec 15 16:02:54 GMT 2023 , Edited by admin on Fri Dec 15 16:02:54 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
RACEMATE -> ENANTIOMER |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|